优化大体积脑转移瘤的全脑放疗:支持AROMA临床试验的计划研究
本研究针对1至10个脑转移瘤且至少一个病灶大于15 cm3、曾接受全脑放疗作为常规治疗一部分的20例患者,设计并评估全脑放疗、海马保护全脑放疗及三种容积旋转调强放疗剂量模型共五种计划。处方剂量为全脑或靶区20 Gy分5次,容积旋转调强放疗计划中对较小病灶给予更高剂量并对内计划靶区行剂量递增。结果显示容积旋转调强放疗计划在脑病灶中剂量分布效率显著优于全脑放疗,尤其剂量递增内计划靶区模型,同时降低正常脑及其他危及器官剂量(p < 0.05)。
要点
- 容积旋转调强放疗计划较全脑放疗在脑病灶中剂量分布效率显著更高,尤其剂量递增内计划靶区模型(p < 0.05)。
- 容积旋转调强放疗计划在提高脑转移瘤剂量的同时降低了正常脑和其他危及器官的剂量。
- 对大体积病灶行剂量递增容积旋转调强放疗可在维持危及器官安全剂量的同时给予更高放疗剂量。
核心结论
- 容积旋转调强放疗计划使脑转移瘤获得更高剂量并最小化危及器官剂量。
- 对大体积病灶行剂量递增容积旋转调强放疗可在维持危及器官安全剂量的同时向大体积病灶递送更高放疗剂量。
研究设计与样本
- 研究纳入20例有1至10个脑转移瘤且至少一个病灶大于15 cm3、曾接受全脑放疗作为常规治疗一部分的患者。
- 为每例患者设计并评估五种放疗计划,包括全脑放疗、海马保护全脑放疗和三种容积旋转调强放疗剂量模型。
- 处方剂量为全脑或靶区20 Gy分5次,容积旋转调强放疗计划中对较小病灶给予更高剂量并对内计划靶区行剂量递增。
- 采用效率指数、靶区与危及器官的平均剂量及D0.1 cc评估治疗计划。
主要发现
- 与全脑放疗相比,容积旋转调强放疗计划在脑病灶中达到显著更高效的剂量分布,尤其剂量递增内计划靶区模型(p < 0.05)。
- 容积旋转调强放疗计划同时最小化正常脑和其他危及器官的剂量(p < 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a novel dose-escalated volumetric modulated arc therapy (VMAT) strategy for patients with single or multiple large brain metastases which can deliver a higher dose to individual lesions for better local control (LC), and to compare dosimetry between whole brain radiotherapy (WBRT), hippocampal-sparing whole brain radiotherapy (HS-WBRT) and different VMAT-based focal radiotherapy approaches. METHODS AND MATERIALS: We identified 20 patients with one to ten brain metastases and at least one lesion larger than 15 cm3 who had received WBRT as part of routine care. For each patient, we designed and evaluated five radiotherapy treatment plans, including WBRT, HS-WBRT and three VMAT dosing models. A dose of 20 Gy in 5 fractions was prescribed to the whole brain or target volumes depending on the plan, with higher doses to smaller lesions and dose-escalated inner planning target volumes (DE-iPTV) in VMAT plans, respectively. Treatment plans were evaluated using the efficiency index, mean dose and D0.1 cc to the target volumes and organs at risk. RESULTS: Compared with WBRT, VMAT plans achieved a significantly more efficient dose distribution in brain lesions, especially with our DE-iPTV model, while minimising the dose to the normal brain and other organs at risks (OARs) (p < 0.05). CONCLUSIONS: VMAT plans obtained higher doses to brain metastases and minimised doses to OARs. Dose-escalated VMAT for larger lesions allows higher radiotherapy doses to be delivered to larger lesions while maintaining safe doses to OARs.
引用
- Chen J, Sinclair G, Rozati H, et al. Improving on whole-brain radiotherapy in patients with large brain metastases: A planning study to support the AROMA clinical trial. Radiother Oncol. 2022. PMID: 35182688. doi:10.1016/j.radonc.2022.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。